IL100896A - Inhaled asthma medications containing non-steroidal anti-inflammatory compounds - Google Patents

Inhaled asthma medications containing non-steroidal anti-inflammatory compounds

Info

Publication number
IL100896A
IL100896A IL100896A IL10089692A IL100896A IL 100896 A IL100896 A IL 100896A IL 100896 A IL100896 A IL 100896A IL 10089692 A IL10089692 A IL 10089692A IL 100896 A IL100896 A IL 100896A
Authority
IL
Israel
Prior art keywords
unw
patients
inhalation
bronchial
effect
Prior art date
Application number
IL100896A
Other languages
English (en)
Hebrew (he)
Other versions
IL100896A0 (en
Original Assignee
Sebastiano Bianco
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sebastiano Bianco filed Critical Sebastiano Bianco
Publication of IL100896A0 publication Critical patent/IL100896A0/xx
Publication of IL100896A publication Critical patent/IL100896A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/02Halogenated hydrocarbons
    • A61K31/025Halogenated hydrocarbons carbocyclic
    • A61K31/03Halogenated hydrocarbons carbocyclic aromatic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • A61K31/405Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/60Salicylic acid; Derivatives thereof
    • A61K31/612Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL100896A 1991-02-09 1992-02-07 Inhaled asthma medications containing non-steroidal anti-inflammatory compounds IL100896A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP91101818 1991-02-09

Publications (2)

Publication Number Publication Date
IL100896A0 IL100896A0 (en) 1992-11-15
IL100896A true IL100896A (en) 1998-02-22

Family

ID=8206393

Family Applications (1)

Application Number Title Priority Date Filing Date
IL100896A IL100896A (en) 1991-02-09 1992-02-07 Inhaled asthma medications containing non-steroidal anti-inflammatory compounds

Country Status (16)

Country Link
US (1) US6051566A (hu)
JP (1) JPH0648958A (hu)
KR (1) KR920016086A (hu)
AT (1) ATE179605T1 (hu)
AU (1) AU662509B2 (hu)
BR (1) BR9200429A (hu)
CA (1) CA2060937A1 (hu)
CZ (1) CZ281970B6 (hu)
DE (1) DE69229070T2 (hu)
HU (1) HUT60917A (hu)
IE (1) IE920427A1 (hu)
IL (1) IL100896A (hu)
MX (1) MX9200571A (hu)
NO (1) NO179893C (hu)
NZ (1) NZ241542A (hu)
ZA (1) ZA92890B (hu)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6946117B1 (en) * 1997-09-29 2005-09-20 Nektar Therapeutics Stabilized preparations for use in nebulizers
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
MXPA02001323A (es) 2000-05-10 2004-07-16 Alliance Pharma Microgranulos con base fosfolipida para la liberacion de farmaco.
US8404217B2 (en) 2000-05-10 2013-03-26 Novartis Ag Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
US6613308B2 (en) * 2000-09-19 2003-09-02 Advanced Inhalation Research, Inc. Pulmonary delivery in treating disorders of the central nervous system
US7256184B2 (en) * 2000-10-16 2007-08-14 Rodriguez Victorio C Treatment of aging disorders in humans
DE60230609D1 (de) * 2001-05-24 2009-02-12 Alexza Pharmaceuticals Inc Verabreichung von nichtsteroidalen entzündungshemmenden wirkstoffen durch inhalation
CA2446904A1 (en) 2001-05-24 2003-04-03 Alexza Molecular Delivery Corporation Delivery of drug esters through an inhalation route
WO2002094242A1 (en) * 2001-05-24 2002-11-28 Alexza Molecular Delivery Corporation Delivery of rizatriptan or zolmitriptan through an inhalation route
US7458374B2 (en) 2002-05-13 2008-12-02 Alexza Pharmaceuticals, Inc. Method and apparatus for vaporizing a compound
US20070122353A1 (en) 2001-05-24 2007-05-31 Hale Ron L Drug condensation aerosols and kits
US7645442B2 (en) 2001-05-24 2010-01-12 Alexza Pharmaceuticals, Inc. Rapid-heating drug delivery article and method of use
DE60230035D1 (de) * 2001-05-24 2009-01-08 Alexza Pharmaceuticals Inc Verabreichung von alprazolam, estazolam, midazolam oder triazolam durch inhalation
US7498019B2 (en) 2001-05-24 2009-03-03 Alexza Pharmaceuticals, Inc. Delivery of compounds for the treatment of headache through an inhalation route
US20030051728A1 (en) 2001-06-05 2003-03-20 Lloyd Peter M. Method and device for delivering a physiologically active compound
WO2003041693A1 (en) * 2001-11-09 2003-05-22 Alexza Molecular Delivery Corporation Delivery of diazepam through an inhalation route
AU2002352726A1 (en) 2001-11-15 2003-06-10 Galileo Laboratories, Inc. Formulations and methods for treatment or amelioration of inflammatory conditions
AU2002363947A1 (en) * 2001-11-21 2003-07-24 Alexza Molecular Delivery Corporation Delivery of caffeine through an inhalation route
US7368102B2 (en) * 2001-12-19 2008-05-06 Nektar Therapeutics Pulmonary delivery of aminoglycosides
CA2483687A1 (en) 2002-05-13 2003-11-20 Alexza Molecular Delivery Corporation Delivery of drug amines through an inhalation route
US20060193788A1 (en) * 2002-11-26 2006-08-31 Hale Ron L Acute treatment of headache with phenothiazine antipsychotics
US20040105818A1 (en) 2002-11-26 2004-06-03 Alexza Molecular Delivery Corporation Diuretic aerosols and methods of making and using them
US7550133B2 (en) * 2002-11-26 2009-06-23 Alexza Pharmaceuticals, Inc. Respiratory drug condensation aerosols and methods of making and using them
CN1717237A (zh) * 2002-11-26 2006-01-04 艾利斯达分子传输公司 洛沙平和阿莫沙平在制备治疗疼痛的药物中的应用
CN1726037B (zh) * 2002-11-26 2010-05-05 艾利斯达医药品公司 抗精神病药用于制备通过吸入传送治疗头痛的药物中的应用
US7913688B2 (en) 2002-11-27 2011-03-29 Alexza Pharmaceuticals, Inc. Inhalation device for producing a drug aerosol
ATE510174T1 (de) 2003-05-21 2011-06-15 Alexza Pharmaceuticals Inc Schlag gezündete unabhängige heizeinheit
US7540286B2 (en) 2004-06-03 2009-06-02 Alexza Pharmaceuticals, Inc. Multiple dose condensation aerosol devices and methods of forming condensation aerosols
US8455437B2 (en) * 2005-02-04 2013-06-04 The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Method to predict and prevent oxygen-induced inflammatory tissue injury
ITMI20050417A1 (it) * 2005-03-15 2006-09-16 Medestea Res & Production S R L Uso di farmaci anti-infiammatori non steroidei per via inalatoria nella terapia della bronchite acuta e cronica
AR059357A1 (es) * 2006-02-09 2008-03-26 Schering Corp Formulaciones farmaceuticas
JP5094197B2 (ja) * 2006-04-27 2012-12-12 第一三共ヘルスケア株式会社 杯細胞過形成を抑制するための抗ヒスタミン剤含有医薬組成物
ES2594867T3 (es) 2007-03-09 2016-12-23 Alexza Pharmaceuticals, Inc. Unidad de calentamiento para usar en un dispositivo de administración de fármaco
DE102008004386A1 (de) * 2008-01-14 2009-07-23 Activaero Gmbh Verwendung eines Acetylsalicylsäuresalzes zur Behandlung viraler Infektionen
JP2011523401A (ja) * 2008-04-29 2011-08-11 ワイス・エルエルシー 炎症を治療するための方法
KR101704815B1 (ko) * 2009-08-21 2017-02-09 포항공과대학교 산학협력단 Il-17 매개 염증질환의 치료를 위한 조합 제제 및 이를 이용한 치료 방법
US20130281405A1 (en) * 2012-04-02 2013-10-24 Lenard M. Lichtenberger Use of pc-nsaids to treat and/or prevent pulmonary inflammation
US9757395B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
EP3607941A1 (en) 2013-04-30 2020-02-12 Otitopic Inc. Dry powder formulations and methods of use
TWI586383B (zh) * 2014-04-18 2017-06-11 林信湧 一種用於治療關節炎之吸入式醫藥組成物及其備製方法
WO2016040570A2 (en) 2014-09-12 2016-03-17 Children's Medical Center Corporation Dietary emulsion formulations and methods for using the same
WO2016196401A1 (en) * 2015-05-29 2016-12-08 The Texas A&M University System Antimicrobial and anti-inflammatory compositions

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5244899A (en) * 1985-02-04 1993-09-14 G. D. Searle And Co. Azabicycloalkyl and azatricycloalkyl amides used to treat inflammation, allergy, asthma and skin disorders
US4885287A (en) * 1988-08-09 1989-12-05 University Of Kentucky Research Foundation Novel method of administering aspirin and dosage forms containing same

Also Published As

Publication number Publication date
NO920504L (no) 1992-08-10
HU9200389D0 (en) 1992-04-28
KR920016086A (ko) 1992-09-24
IE920427A1 (en) 1992-08-12
JPH0648958A (ja) 1994-02-22
MX9200571A (es) 1992-12-01
DE69229070D1 (de) 1999-06-10
NO920504D0 (no) 1992-02-07
DE69229070T2 (de) 1999-11-18
AU662509B2 (en) 1995-09-07
NO179893C (no) 1997-01-08
IL100896A0 (en) 1992-11-15
BR9200429A (pt) 1992-10-13
ATE179605T1 (de) 1999-05-15
NZ241542A (en) 1996-05-28
NO179893B (no) 1996-09-30
CZ281970B6 (cs) 1997-04-16
CA2060937A1 (en) 1992-08-10
AU1077292A (en) 1992-08-13
ZA92890B (en) 1992-12-30
CS35292A3 (en) 1992-08-12
HUT60917A (en) 1992-11-30
US6051566A (en) 2000-04-18

Similar Documents

Publication Publication Date Title
US6051566A (en) Anti-reactive anti-asthmatic activity of non-steroidal anti-inflammatory drugs by inhalation
ES2309503T3 (es) Medicamento que comprende un agonista beta 2 de larga duracion, muy potente, en combinacion con otros ingredientes activos.
Tashkin et al. Bronchial effects of aerosolized Δ9-tetrahydrocannabinol in healthy and asthmatic subjects
PL199442B1 (pl) Kompozycja farmaceutyczna oparta na związkach antycholinergicznych i beta-mimetycznych oraz jej zastosowanie
CA2024872C (en) Medicaments
JP6300828B2 (ja) 口腔粘膜炎を治療するための口腔殺菌性組成物
AU2005210083A1 (en) Novel combination of anticholinergic and beta mimetics for the treatment of respiratory diseases
LV12201B (en) USE OF NITROGEN OXIDE FOR BRONHOSTENOSE TREATMENT OR PROFILE
US5366967A (en) Potentiation of the anti-reactive-antiasthmatic effect of inhaled loop diuretics by inhaled non-steroidal anti-inflammatory drugs
EP0499143B1 (en) Anti-reactive anti-asthmatic activity of acetylsalicylic acid by inhalation
BRPI0610498A2 (pt) uso de roflumilast,composição farmacêutica, produto de combinação e kit para o tratamento de hipertensão pulmonar
Bleecker et al. Acute bronchodilating effects of ipratropium bromide and theophylline in chronic obstructive pulmonary disease
Joos et al. The effect of aerosolized SK&F 104353-Z2 on the bronchoconstrictor effect of leukotriene D4 in asthmatics
PT866711E (pt) Montirelina para inibição da apneia do sono
Mutoh et al. Effects of nitrous oxide on mask induction of anesthesia with sevoflurane or isoflurane in dogs
NZ260290A (en) Use of a non-steroidal anti-inflammatory drug in the preparation of anti-asthmatic inhalant compositions
Evans et al. L‐648,051, a novel cysteinyl‐leukotriene antagonist is active by the inhaled route in man.
WO2010009288A1 (en) Compositions and uses of antiviral active pharmaceutical agents
Godin et al. Acute bronchoconstriction caused by Beclovent and not Vanceril
RU2625766C1 (ru) Средство для экстренного восстановления голоса при внезапной афонии
Ghany Hassan et al. Study of the hemodynamic effect of inhaled milrinone versus inhaled nitroglycerin on mechanically ventilated patients with pulmonary hypertension after mitral valve replacement surgeries
Sestini et al. Protective Effect of Furosemide, Administered Using a Pressurized Metered Dose Inhaler and a Spacer Device, on the Bronchial Obstructive Response to Ultrasonically Nebulized Distilled Water
Hyde et al. POSTER/DISCUSSION SESSION 7: DIAGNOSTIC, PROPHYLACTIC AND THERAPEUTIC APPLICATIONS OF AEROSOLS
Foged et al. Terbutaline Depot Tablets in Childhood Asthma: A Double‐Blind Controlled Study
JP2018048155A (ja) 口腔粘膜炎を治療するための口腔殺菌性組成物

Legal Events

Date Code Title Description
FF Patent granted
RH Patent void